215 related articles for article (PubMed ID: 18430496)
1. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
[TBL] [Abstract][Full Text] [Related]
2. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
[TBL] [Abstract][Full Text] [Related]
4. Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan.
Huang WT; Chen WW; Yang HW; Chen WC; Chao YN; Huang YW; Chuang JH; Kuo HS
Vaccine; 2010 Oct; 28(44):7161-6. PubMed ID: 20804804
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
[TBL] [Abstract][Full Text] [Related]
7. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
Kelly C; Arnold R; Galloway Y; O'Hallahan J
Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
[TBL] [Abstract][Full Text] [Related]
9. [Post licensure safety surveillance for Prevenar].
Bensouda-Grimaldi L; Jonville-Béra AP; Autret-Leca E
Arch Pediatr; 2007 Jul; 14(7):870-4. PubMed ID: 17442548
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of vaccine breakthrough cases following MeNZB vaccination.
McNicholas A; Galloway Y; Martin D; Sexton K; O'Hallahan J
N Z Med J; 2008 Apr; 121(1272):38-46. PubMed ID: 18425153
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.
McNicholas A; Galloway Y; Stehr-Green P; Reid S; Radke S; Sexton K; Kieft C; Macdonald C; Neutze J; Drake R; Isaac D; O'Donnell M; Tatley M; Oster P; O'Hallahan J
Hum Vaccin; 2007; 3(5):196-204. PubMed ID: 17660718
[TBL] [Abstract][Full Text] [Related]
13. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
14. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System.
Ball R; Braun MM; Mootrey GT;
Clin Infect Dis; 2001 May; 32(9):1273-80. PubMed ID: 11303261
[TBL] [Abstract][Full Text] [Related]
15. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study.
Velentgas P; Bohn RL; Brown JS; Chan KA; Gladowski P; Holick CN; Kramer JM; Nakasato C; Spettell CM; Walker AM; Zhang F; Platt R
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1226-34. PubMed ID: 18956428
[TBL] [Abstract][Full Text] [Related]
16. Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
Hill GR; Ashton J; Harrison-Woolrych M
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1217-26. PubMed ID: 17661435
[TBL] [Abstract][Full Text] [Related]
17. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
Miller M; Turner N
N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
[No Abstract] [Full Text] [Related]
18. The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand.
Stehr-Green P; Galloway Y; Kieft C; McNicholas A
N Z Med J; 2007 Oct; 120(1263):U2746. PubMed ID: 17972966
[TBL] [Abstract][Full Text] [Related]
19. MeNZB vaccine and epidemic control: when do you stop vaccinating?
Loring BJ; Turner N; Petousis-Harris H
Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
[TBL] [Abstract][Full Text] [Related]
20. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
